Literature DB >> 21750222

Inhibition of dynamin by dynole 34-2 induces cell death following cytokinesis failure in cancer cells.

Megan Chircop1, Swetha Perera, Anna Mariana, Hui Lau, Maggie P C Ma, Jayne Gilbert, Nigel C Jones, Christopher P Gordon, Kelly A Young, Andrew Morokoff, Jennette Sakoff, Terence J O'Brien, Adam McCluskey, Phillip J Robinson.   

Abstract

Inhibitors of mitotic proteins such as Aurora kinase and polo-like kinase have shown promise in preclinical or early clinical development for cancer treatment. We have reported that the MiTMAB class of dynamin small molecule inhibitors are new antimitotic agents with a novel mechanism of action, blocking cytokinesis. Here, we examined 5 of the most potent of a new series of dynamin GTPase inhibitors called dynoles. They all induced cytokinesis failure at the point of abscission, consistent with inhibition of dynamin while not affecting other cell cycle stages. All 5 dynoles inhibited cell proliferation (MTT and colony formation assays) in 11 cancer cell lines. The most potent GTPase inhibitor, dynole 34-2, also induced apoptosis, as revealed by cell blebbing, DNA fragmentation, and PARP cleavage. Cell death was induced specifically following cytokinesis failure, suggesting that dynole 34-2 selectively targets dividing cells. Dividing HeLa cells were more sensitive to the antiproliferative properties of all 5 dynoles compared with nondividing cells, and nontumorigenic fibroblasts were less sensitive to cell death induced by dynole 34-2. Thus, the dynoles are a second class of dynamin GTPase inhibitors, with dynole 34-2 as the lead compound, that are novel antimitotic compounds acting specifically at the abscission stage.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21750222     DOI: 10.1158/1535-7163.MCT-11-0067

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  21 in total

1.  Synthesis of Dynole 34-2, Dynole 2-24 and Dyngo 4a for investigating dynamin GTPase.

Authors:  Mark J Robertson; Fiona M Deane; Phillip J Robinson; Adam McCluskey
Journal:  Nat Protoc       Date:  2014-03-20       Impact factor: 13.491

2.  Cytokinetic abscission is an acute G1 event.

Authors:  Ofir Gershony; Tal Pe'er; Meirav Noach-Hirsh; Natalie Elia; Amit Tzur
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 3.  Dynamin, a membrane-remodelling GTPase.

Authors:  Shawn M Ferguson; Pietro De Camilli
Journal:  Nat Rev Mol Cell Biol       Date:  2012-01-11       Impact factor: 94.444

4.  Dynole 34-2 and Acrylo-Dyn 2-30, Novel Dynamin GTPase Chemical Biology Probes.

Authors:  Jennifer R Baker; Nicholas S O'Brien; Kate L Prichard; Phillip J Robinson; Adam McCluskey; Cecilia C Russell
Journal:  Methods Mol Biol       Date:  2022

5.  Novel dynamin 2 mutations in adult T-cell acute lymphoblastic leukemia.

Authors:  Zheng Ge; Min Li; Gang Zhao; Lichan Xiao; Yan Gu; Xilian Zhou; Michael D Yu; Jianyong Li; Sinisa Dovat; Chunhua Song
Journal:  Oncol Lett       Date:  2016-08-10       Impact factor: 2.967

6.  Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma.

Authors:  Jia-Xi Song; Fang-Qiu Li; Wang-Li Cao; Xuan Jia; Li-Ning Shi; Jing-Fen Lu; Chun-Fang Ma; Qian-Qian Kong
Journal:  Target Oncol       Date:  2013-08-14       Impact factor: 4.493

7.  Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein.

Authors:  Magdalena Anna Krzyzaniak; Michael Thomas Zumstein; Juan Atilio Gerez; Paola Picotti; Ari Helenius
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

8.  Inhibition of clathrin by pitstop 2 activates the spindle assembly checkpoint and induces cell death in dividing HeLa cancer cells.

Authors:  Charlotte M Smith; Volker Haucke; Adam McCluskey; Phillip J Robinson; Megan Chircop
Journal:  Mol Cancer       Date:  2013-01-17       Impact factor: 27.401

9.  Dynamin inhibitors impair endocytosis and mitogenic signaling of PDGF.

Authors:  Łukasz Sadowski; Kamil Jastrzębski; Yannis Kalaidzidis; Carl-Henrik Heldin; Carina Hellberg; Marta Miaczynska
Journal:  Traffic       Date:  2013-03-12       Impact factor: 6.215

Review 10.  A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target.

Authors:  Delphine Trochet; Marc Bitoun
Journal:  J Exp Clin Cancer Res       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.